1. FV Vectors as Alternative Gene Vehicles for Gene Transfer in HSCs
- Author
-
Emmanouil Simantirakis, George Vassilopoulos, and Ioannis Tsironis
- Subjects
0301 basic medicine ,foamy virus ,Genetic enhancement ,Population ,Genetic Vectors ,lcsh:QR1-502 ,Drug Evaluation, Preclinical ,Computational biology ,Review ,Gene delivery ,Biology ,HSC ,lcsh:Microbiology ,FV gene transfer to HSCs ,Cell therapy ,03 medical and health sciences ,0302 clinical medicine ,Transduction, Genetic ,Virology ,Animals ,Humans ,education ,Gene ,education.field_of_study ,gene therapy alternatives ,Gene Transfer Techniques ,Genetic Therapy ,Hematopoietic Stem Cells ,gene therapy ,Genetically modified organism ,Haematopoiesis ,Disease Models, Animal ,030104 developmental biology ,Infectious Diseases ,gene marking ,030220 oncology & carcinogenesis ,Spumavirus ,Stem cell - Abstract
Hematopoietic Stem Cells (HSCs) are a unique population of cells, capable of reconstituting the blood system of an organism through orchestrated self-renewal and differentiation. They play a pivotal role in stem cell therapies, both autologous and allogeneic. In the field of gene and cell therapy, HSCs, genetically modified or otherwise, are used to alleviate or correct a genetic defect. In this concise review, we discuss the use of SFVpsc_huHSRV.13, formerly known as Prototype Foamy Viral (PFV or FV) vectors, as vehicles for gene delivery in HSCs. We present the properties of the FV vectors that make them ideal for HSC delivery vehicles, we review their record in HSC gene marking studies and their potential as therapeutic vectors for monogenic disorders in preclinical animal models. FVs are a safe and efficient tool for delivering genes in HSCs compared to other retroviral gene delivery systems. Novel technological advancements in their production and purification in closed systems, have allowed their production under cGMP compliant conditions. It may only be a matter of time before they find their way into the clinic.
- Published
- 2020